On March 7- 8, 2017, Defined Health convened the 28th annual Cancer Progress meeting in New York City. Since 1985, Cancer Progress has served as a unique forum for an insightful and frank discussion about the scientific progress being made in oncology from the perspectives of clinical, regulatory, commercial, payer, patient advocacy, and investor stakeholders. As a companion piece to the meeting (or a primer for those who were unable to attend), the following summarizes some key takeaways and their implications for those looking to establish or maintain relevance in this fast-paced competitive landscape. Key issues addressed herein include the emerging roles of immuno-oncology (IO) vs. non-IO therapies, collaboration vs. competition, and value vs. unmitigated pricing within the evolving oncology landscape. The report closes with some thoughts about where cancer management may be going based on an assessment of present trends.